Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial*
Jennifer Tom, Fang Cai, Lothar Wiese(Zealand University Hospital), Celia J. F. Lin, Nidhi Rohatgi(The University of Texas MD Anderson Cancer Center), Jacqueline McBride, Iván O. Rosas(Brigham and Women's Hospital), Cor H. van der Leest(Roche (Canada)), Farrah Kheradmand(Baylor College of Medicine), Jordi Carratalà(Instituto de Salud Carlos III), Kevin G. Blyth(Queen Elizabeth University Hospital), David Summers(Roche (United Kingdom)), Carrie M. Rosenberger(California Institute for Regenerative Medicine), Paolo Bonfanti(University of California San Diego), Thomas Benfield(University of Copenhagen), Min Bao(California Institute of Technology), Larry Tsai, Derrick S. Haslem(Intermountain St. George Regional Hospital), Bruno François(Inserm), Charles Edouard Luyt(Sorbonne Université), Montserrat Carrasco‐Triguero(Sangamo BioSciences (United States)), William Stubbings(Roche (Switzerland)), Aditi Qamra(National University of Singapore)
Cited by 42
Related Papers
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
|New England Journal of Medicine|2018|894
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890